Adding ribociclib to hormone therapy extends lives of women with most common breast cancer

A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy.Ribociclib is considered a cyclin-dependent kinase inhibitor that works by blocking the activity of proteins called cyclin-dependent kinase 4/6 enzymes, which promote cell division and cancer growth.The study involved 672 women aged 25 to 59 when the study began who had advanced hormone-receptor positive/HER2- breast cancer. Seventy percent of the women who took the combination therapy were alive after 42 months, compared to 46% for women who treated with only the hormone therapy.The  study is featured in a press briefing today at the 2019 American Society of Clinical Oncology annual meeting and will be published in the New England Journal of Medicine on June 4.Dr. Sara Hurvitz, director of the Breast Cancer Clinical Research Program at theUCLA Jonsson Comprehensive Cancer Center, said the study is the first to show a significant benefit in overall survival for women in this age group with metastatic hormone-receptor positive breast cancer.“This trial was unique because it looks at younger women who haven’t gone through menopause,” said Hurvitz, the study’s lead author, who is also an associate professor of hematology/oncology at theDavid Geffen School of Medicine at UCLA. “This is an important group to stud...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news

Related Links:

AbstractBackgroundAim: To clarify the clinicopathological characters and treatments and prognosis in elderly breast cancer patients using the Japanese Breast Cancer Registry (JBCR) system.MethodsWe reviewed data from JBCR, which is the nation-wide registry of newly diagnosed and operated primary breast cancer patients in Japan. To clarify its characteristics, we compared elderly patients aged 75 and over (elderly) with aged from 65 to 74 (young-old; y-o) and that from 55 to 64 (post-menopausal; p-m), respectively.ResultsIn total 132,240 cases diagnosed between 2004 and 2011 were reviewed (elderly; n  = 27,385...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe provisional MTD for RAD140 is 100  mg QD. RAD140 is a novel oral AR-targeted agent for treatment of ER+ mBC with an acceptable safety profile and preliminary evidence of target engagement and antitumor activity. NCT03088527.Clinical trial identificationNCT03088527.Legal entity responsible for the studyRadius Health, Inc.FundingRadius Health, Inc.DisclosureE. Hamilton: Advisory / Consultancy: Flatiron Health; Travel / Accommodation / Expenses: Amgen; Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Bayer; Travel / Accommodation /...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: TPA-treated patients whose Ki67 decreased by ≥30% demonstrated a selective anti-proliferative signal, with a potentially important effect on HER2 amplicon genes. Evaluation of SPRMs in a neoadjuvant trial is merited, with attention to predictors of response to SPRM therapy, and inclusion of pre and postmenopausal women. PMID: 31570566 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Conclusions: In this cohort of women with elevated risk, high serum 25(OH)D levels and regular vitamin D supplement use were associated with lower rates of incident, postmenopausal breast cancer over 5 y of follow-up. These results may help to establish clinical benchmarks for 25(OH)D levels; in addition, they support the hypothesis that vitamin D supplementation is useful in breast cancer prevention. https://doi.org/10.1289/EHP943 About This Article Received: 09 August 2016 Revised: 23 January 2017 Accepted: 06 February 2017 Published: 06 July 2017 Address correspondence to C. R. Weinberg, 111 TW Alexander Dr., Rese...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
Background: Alcohol is a recognized risk factor for invasive breast cancer, but few studies involve African American women. Methods: The current analysis included 22,338 women (5,108 cases of invasive breast cancer) from the African American Breast Cancer Epidemiology and Risk (AMBER) Consortium. The association between number of alcoholic drinks per week (dpw) and breast cancer was estimated using logistic regression, adjusting for potential confounders, and stratifying by breast cancer subtype. Results: Approximately 35% of controls were current drinkers at interview. Women who reported current drinking of ≥14 dpw had...
Source: Cancer Epidemiology Biomarkers and Prevention - Category: Cancer & Oncology Authors: Tags: Research Articles Source Type: research
Conclusions: The addition of everolimus to fulvestrant significantly improved PFS in post-menopausal women with AI-resistant MBC. Everolimus used without prophylactic corticosteroid mouthwash exhibited a similar rate of oral mucositis and overall AE profile when combined with fulvestrant as when combined with exemestane.Keywords: advanced breast cancer, PrECOG 0102, endocrine resistance, everolimus, exemestane, hormone receptor-positive, mTOR inhibitor, postmenopausal.Citation Format: Kornblum NS, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, Leach J, Truica CI, Wolff AC, Soori GS, ...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: General Session Abstracts Source Type: research
Authors: Ejlertsen B Abstract With long-term follow-up, the DBCG 77B trial demonstrates that oral single-agent cyclophosphamide significantly reduces the risk of recurrence and mortality as compared with no systemic therapy in pre-menopausal patients with high-risk early breast cancer. DBCG 77B is the only randomised trial assessing single-agent cyclophosphamide; and a second comparison suggests that its benefits are comparable to what may be achieved by classic CMF. The lack of benefits from adding methotrexate and fluorouracil to cyclophosphamide paved the way for combining cyclophosphamide with anthracyclines an...
Source: Danish Medical Journal - Category: Journals (General) Tags: Dan Med J Source Type: research
For over a half century the NSABP has conducted clinical trials to ascertain optimal therapy in patients with early breast cancer. The trials, performed in chronologic sequential manner, provide a well- documented compilation of evolving biologic theories disclosing both flaws and occasional episodes of perspicacity in a disinterested manner. In the process, this endeavor has contributed to establishing standards of care; a tribute to the 100,000 women who participated.Two landmark studies started in the 1970s (B04, B06) initiated the retreat from radical mastectomy and established the propriety of breast preserving operat...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Invited Speaker Abstracts Source Type: research
Background: Across multiple studies performed in several countries with widely instituted screening mammography programs at different intervals between exams, up to 19% of breast cancer identified is in patients whose disease would otherwise go undetected and not have caused any ill effect if left untreated. Recent advances in pathologic and multigene assays have demonstrated promise to better identify low risk breast cancer and appropriately tailor treatments. Nonetheless, most women who may have such low-risk, estrogen receptor expressing lesions continue to be offered only an aggressive treatment paradigm. This most com...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
The current NCCN treatment guidelines for ER+ breast cancer involves the use of approved agents such as fulvestrant, tamoxifen and aromatase inhibitors that either inhibit estrogen production or block estrogen receptor binding. While the initial treatment regimens with these selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) is often successful, many women eventually relapse with more aggressive forms of endocrine-resistant disease. To begin to overcome some of the challenges associated with current therapies including exposure limitations and intramuscular administration, we h...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Ongoing Clinical Trials Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Endocrine Therapy | Hematology | HER2 | Hormonal Therapy | Hormones | Hospitals | Men | Menopause | Oral Cancer | Study | Taiwan Health | Texas University | Universities & Medical Training | Women